Immunotherapy boosts standard treatment for head and neck cancer in early trial
Disease control
Completed
This early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe and effective for people with advanced head and neck cancer. 59 participants received pembrolizumab before, during, and after their regular treatment. The goal was…
Phase: PHASE1 • Sponsor: Sanford Health • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC